Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK2 | Q92630 | 14/20 | 0.60 |
| ▸ | DYRK1A | Q13627 | 14/20 | 0.60 |
| ▸ | DYRK1B | Q9Y463 | 14/20 | 0.60 |
| ▸ | CLK4 | Q9HAZ1 | 12/20 | 0.60 |
| ▸ | CLK2 | P49760 | 11/20 | 0.60 |
| ▸ | CLK3 | P49761 | 9/20 | 0.60 |
| ▸ | GSK3B | P49841 | 6/20 | 0.60 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | CLK1 | P49759 | 12/20 | 0.44 |
| ▸ | DYRK3 | O43781 | 9/20 | 0.41 |
| ▸ | DYRK4 | Q9NR20 | 6/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PRKCB | P05771 | 1/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18280035 | 0.79 | GRM5 (0.43) | DYRK2DYRK1ADYRK1BCLK4CLK2 | |
| SCHEMBL4959967 | 0.76 | ESR2 (0.46) | GRM5 | |
| SCHEMBL18280097 | 0.76 | GRM5 (0.46) | GRM5 | |
| SCHEMBL29826757 | 0.76 | JAK2 (0.43) | DYRK2DYRK1ADYRK1BCLK4CLK2 | |
| SCHEMBL23970345 | 0.75 | CLK4 (0.60) | DYRK2DYRK1ADYRK1BCLK4CLK2 | |
| SCHEMBL3642719 | 0.75 | GRM5 (0.47) | GRM5 | |
| SCHEMBL1009267 | 0.75 | ESR2 (0.53) | GRM5 | |
| SCHEMBL14720896 | 0.74 | GRM5 (0.46) | GRM5 | |
| SCHEMBL1870570 | 0.74 | NR1H2 (0.54) | GRM5 | |
| SCHEMBL5497099 | 0.74 | MEN1 (0.55) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | OPRM1, GRM5, OPRD1 | DYRK2 587/4885DYRK1A 840/4885DYRK1B 723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.